Latest From Cerecor Inc.
Pharma sells the rights to Germany’s Cheplapharm, which obtained EU/Russia rights in October. Cerecor will acquire Aevi Genomics for $16.1m plus contingent value rights.
Tris acquires Pfizer subsidiary Nextwave, which developed pair of ADHD drugs using Tris delivery technology. Lilly gets oral CGRP candidate from Chugai, while Dova signs US co-promotion partner for Doptelet.
Already a significant investor in the health care technology firm, buyout will give Roche access to substantial real-world cancer development data. Astellas acquires stem cell-focused Universal Cells.
Pharmas have shied away from the challenging antidepressant market in recent years, but two late-stage ketamine-like candidates are leading the pack of novel agents in development.
- Specialty Pharmaceuticals
- Therapeutic Areas
- Metabolic Disorders
- Neurology, Nervous System
- Cerecor Corp.
- North America
- Parent & Subsidiaries
- Cerecor Inc.
- Senior Management
Joe Miller, CFO
Perry Calias, PhD, CSO & Head, R&D
James A Harrell, Jr., Chief Commercial Officer
- Contact Info
Phone: (410) 522-8707
540 Gaither Rd.
Rockville, MD 20850
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.